Merck KGaA (NASDAQ:MKGAY) has received a consensus rating of “Hold” from the seven analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $66.67.

MKGAY has been the topic of a number of research reports. HSBC Holdings plc lowered shares of Merck KGaA from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Deutsche Bank AG lowered shares of Merck KGaA from a “buy” rating to a “hold” rating in a research report on Wednesday.

COPYRIGHT VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/26/merck-kgaa-nasdaqmkgay-given-average-recommendation-of-hold-by-brokerages-2.html.

Shares of Merck KGaA (MKGAY) traded down 0.62% during midday trading on Wednesday, hitting $38.36. Merck KGaA has a 52-week low of $32.53 and a 52-week high of $42.02. The firm’s 50 day moving average is $39.80 and its 200 day moving average is $38.15. The stock has a market cap of $50.01 billion and a price-to-earnings ratio of 27.99.

Merck KGaA Company Profile

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.

Analyst Recommendations for Merck KGaA (NASDAQ:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.